WO2010099044A9 - Traitement de troubles liés à l'immunosuppression - Google Patents

Traitement de troubles liés à l'immunosuppression Download PDF

Info

Publication number
WO2010099044A9
WO2010099044A9 PCT/US2010/024735 US2010024735W WO2010099044A9 WO 2010099044 A9 WO2010099044 A9 WO 2010099044A9 US 2010024735 W US2010024735 W US 2010024735W WO 2010099044 A9 WO2010099044 A9 WO 2010099044A9
Authority
WO
WIPO (PCT)
Prior art keywords
immunosuppression
treatment
related disorders
disorders
Prior art date
Application number
PCT/US2010/024735
Other languages
English (en)
Other versions
WO2010099044A2 (fr
Inventor
James Wang
Lufen Chang
Yun Yen
Original Assignee
StemBios Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by StemBios Technologies, Inc. filed Critical StemBios Technologies, Inc.
Priority to ES10746666.6T priority Critical patent/ES2582582T3/es
Priority to JP2011551250A priority patent/JP5809068B2/ja
Priority to CN201080008875.6A priority patent/CN102325537B/zh
Priority to EP10746666.6A priority patent/EP2400971B1/fr
Publication of WO2010099044A2 publication Critical patent/WO2010099044A2/fr
Publication of WO2010099044A9 publication Critical patent/WO2010099044A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/US2010/024735 2009-02-24 2010-02-19 Traitement de troubles liés à l'immunosuppression WO2010099044A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES10746666.6T ES2582582T3 (es) 2009-02-24 2010-02-19 Células madre de tipo blastómero para uso en el tratamiento de trastorno proliferativo celular e inmunodeficiencia
JP2011551250A JP5809068B2 (ja) 2009-02-24 2010-02-19 免疫抑制−関連疾患の治療
CN201080008875.6A CN102325537B (zh) 2009-02-24 2010-02-19 免疫抑制相关疾病的治疗药物
EP10746666.6A EP2400971B1 (fr) 2009-02-24 2010-02-19 Cellules souches de type blastomère pour le traitement des maladies de prolifération cellulaire et de l'immunodéficience

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/391,581 2009-02-24
US12/391,581 US8563307B2 (en) 2009-02-24 2009-02-24 Treatment of immunosuppression-related disorders

Publications (2)

Publication Number Publication Date
WO2010099044A2 WO2010099044A2 (fr) 2010-09-02
WO2010099044A9 true WO2010099044A9 (fr) 2010-12-16

Family

ID=42631141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/024735 WO2010099044A2 (fr) 2009-02-24 2010-02-19 Traitement de troubles liés à l'immunosuppression

Country Status (7)

Country Link
US (2) US8563307B2 (fr)
EP (1) EP2400971B1 (fr)
JP (1) JP5809068B2 (fr)
CN (1) CN102325537B (fr)
ES (1) ES2582582T3 (fr)
TW (1) TWI496888B (fr)
WO (1) WO2010099044A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563307B2 (en) 2009-02-24 2013-10-22 James Wang Treatment of immunosuppression-related disorders
US8679474B2 (en) 2010-08-04 2014-03-25 StemBios Technologies, Inc. Somatic stem cells
WO2012054792A2 (fr) * 2010-10-22 2012-04-26 Virginia Commonwealth University Composition et méthode utilisées pour le traitement immunologique du cancer, la prévention de la récidive et des métastases du cancer, et l'annulation des effets des cellules immunosuppressives
TWI614340B (zh) 2011-09-28 2018-02-11 幹細胞生物科技股份有限公司 體幹細胞及其製備方法
WO2013176785A1 (fr) * 2012-05-21 2013-11-28 The Trustees Of Columbia University In The City Of New York Facteur de la famille du trèfle et ses utilisations
EP2929013B1 (fr) 2012-12-06 2020-02-05 Stembios Technologies, Inc. Cellules souches lgr5+ somatiques
EP2746770A1 (fr) * 2012-12-21 2014-06-25 Stembios Technologies, Inc. Procédé pour évaluer l'effet d'action sur un sujet basé sur des dynamiques cellulaires de tiges
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
EP3302555A4 (fr) 2015-05-29 2018-07-11 Amphivena Therapeutics, Inc. Procédés d'utilisation de protéines de liaison cd3 et cd33 bispécifiques

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2936171B2 (ja) 1989-09-01 1999-08-23 東ソー株式会社 血清アルブミンの製造方法
US6004807A (en) 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
US6916654B1 (en) 1992-06-29 2005-07-12 Oklahoma Medical Research Foundation Universal donor cells
AU6869198A (en) 1997-03-25 1998-10-20 Morphogenesis, Inc. Universal stem cells
AU1705599A (en) 1997-11-26 1999-06-15 Allegheny University Of The Health Sciences Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood
WO1999050392A1 (fr) 1998-03-31 1999-10-07 Geron Corporation Techniques et compositions permettant de faire apparaitre une reponse immunitaire a un antigene de telomerase
US6080399A (en) 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
JP3553858B2 (ja) 1999-08-25 2004-08-11 東洋紡績株式会社 血管網類似構造体を有する細胞培養用モジュール
US20030161817A1 (en) 2001-03-28 2003-08-28 Young Henry E. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US7575921B2 (en) 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US20020151050A1 (en) 2000-10-30 2002-10-17 Vacanti Charles A. Isolation of spore-like cells from tissues exposed to extreme conditions
JP3977136B2 (ja) 2001-05-22 2007-09-19 キヤノン株式会社 コイルユニット
US7316932B2 (en) 2001-10-01 2008-01-08 Stemcell Technologies Inc. Method for separating cells
US7736892B2 (en) 2002-02-25 2010-06-15 Kansas State University Research Foundation Cultures, products and methods using umbilical cord matrix cells
EP2299274A1 (fr) 2002-03-07 2011-03-23 Medical Research Council Empreintes SCD
US20050158328A1 (en) 2002-06-06 2005-07-21 Immunicum Ab Method and composition for producing a cellular allogeneic vaccine
AU2003287429A1 (en) 2002-11-01 2004-06-07 Five Prime Therapeutics, Inc. Stem cell libraries
WO2004044158A2 (fr) 2002-11-08 2004-05-27 The Johns Hopkins University Cultures de cellules souches embryonnaires humaines, et compositions et procedes de culture correspondants
US20050003533A1 (en) 2003-05-08 2005-01-06 Pawel Kalinski Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
US20090004661A1 (en) 2003-05-26 2009-01-01 Reliance Life Sciences Pvt Ltd. Method of growing mesenchymal stem cells from bone marrow
ES2265199B1 (es) 2003-06-12 2008-02-01 Cellerix, S.L. Celulas madre adultas multipotentes procedentes de condrocitos desdiferenciados y sus aplicaciones.
JP4750697B2 (ja) 2003-06-25 2011-08-17 オタワ ヘルス リサーチ インスティテュート 幹細胞の成長及び分化を調節する方法及び組成物
US7622108B2 (en) 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
WO2006028723A1 (fr) * 2004-09-03 2006-03-16 Moraga Biotechnology Inc. Cellules souches de type blastomeres totipotentes non embryonnaires et procedes associes
US20090104695A1 (en) 2004-12-29 2009-04-23 Etti Ben Shushan Stem Cells Culture Systems
US8846395B2 (en) 2005-06-01 2014-09-30 Wisconsin Alumni Research Foundation Generation of mature myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+progenitors
BRPI0612672B8 (pt) 2005-06-24 2021-05-25 Cerule Llc composição de extrato aquoso de alga verde-azulada
AU2006286149B2 (en) 2005-08-29 2012-09-13 Technion Research And Development Foundation Ltd. Media for culturing stem cells
US20080305079A1 (en) 2006-01-06 2008-12-11 Mount Sinai School Of Medicine Of New York University Myeloid Suppressor Cells, Methods For Preparing Them, and Methods For Using Them For Treating Autoimmunity
CA2640087A1 (fr) 2006-01-25 2007-08-02 Mount Sinai School Of Medicine Procedes et compositions pour la modulation de la mobilisation de cellules souches
EP1991666A4 (fr) 2006-02-27 2009-06-10 Moraga Biotech Corp Cellules souches totipotentes non embryonnaires de type blastomères et méthodes
MY169496A (en) 2006-06-27 2019-04-15 Nutratec S R L Extracts of aphanizomenon flos aquae and nutritional, cosmetic and pharmaceutical compositions containing the same
EP1894941A1 (fr) 2006-09-01 2008-03-05 Institut Pasteur Traitment du carcinome du col de l'utérus avec une adenylate cyclase portant des antigenes HPV
US8759090B2 (en) 2006-10-30 2014-06-24 University Of Central Florida Research Foundation, Inc. Stem cell banking system
US20090155225A1 (en) 2006-11-02 2009-06-18 Mariusz Ratajczak Uses and isolation of very small of embryonic-like (vsel) stem cells
US20090104160A1 (en) 2007-02-01 2009-04-23 Moraga Biotechnology Corporation Mobilization of Stem Cells After Trauma and Methods Therefor
US20090053182A1 (en) 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
PL3009148T3 (pl) 2007-07-02 2019-03-29 Oncomed Pharmaceuticals, Inc. Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
CA2693144A1 (fr) 2007-07-17 2009-01-22 The General Hospital Corporation Methodes d'identification et d'enrichissement de populations de cellules souches cancereuses ovariennes et de cellules souches somatiques ovariennes et utilisations associees
WO2009061024A1 (fr) 2007-11-09 2009-05-14 Rnl Bio Co., Ltd Procédé d'isolement et de culture de cellules souches adultes issues d'épithélium amniotique humain
WO2009136283A2 (fr) 2008-05-08 2009-11-12 Coretherapix Slu Population de cellules souches adultes multipotentes
CN102333861A (zh) 2008-09-30 2012-01-25 路易斯维尔大学研究基金会有限公司 用于分离非常小的胚胎样(vsel)干细胞的方法
WO2010056341A2 (fr) 2008-11-12 2010-05-20 The University Of Vermont And State Agriculture College Compositions et procédés pour la réparation tissulaire
WO2010083203A2 (fr) * 2009-01-13 2010-07-22 StemBios Technologies, Inc. Cellules souches non embryonnaires et leurs utilisations
PL3061808T3 (pl) 2009-02-03 2021-02-08 Koninklijke Nederlandse Akademie Van Wetenschappen Podłoże do hodowli nabłonkowych komórek macierzystych i organoidów zawierających wspomniane komórki macierzyste
EP2412800A1 (fr) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Organoïde du foie, ses utilisations et son procédé de culture pour l'obtenir
US8563307B2 (en) 2009-02-24 2013-10-22 James Wang Treatment of immunosuppression-related disorders
US20140219952A1 (en) 2010-03-23 2014-08-07 The Johns Hopkins University Methods of treatment using stem cell mobilizers
CA2835313A1 (fr) 2010-05-07 2011-11-10 Institut De Recherches Cliniques De Montreal Modulation de gfi1b et utilisations de celle-ci
US8623642B2 (en) 2010-08-04 2014-01-07 StemBios Technologies, Inc. Somatic stem cells
US8679474B2 (en) 2010-08-04 2014-03-25 StemBios Technologies, Inc. Somatic stem cells
CN102008650B (zh) 2010-12-16 2017-02-15 天津市医药科学研究所 一种治疗肿瘤的复方中药制剂及其制备方法
TWI614340B (zh) 2011-09-28 2018-02-11 幹細胞生物科技股份有限公司 體幹細胞及其製備方法
EP2929013B1 (fr) 2012-12-06 2020-02-05 Stembios Technologies, Inc. Cellules souches lgr5+ somatiques
US20140377760A1 (en) 2013-06-24 2014-12-25 StemBios Technologies, Inc. Method for increasing number of stem cells in human or animal bodies
CN105687245A (zh) 2014-12-13 2016-06-22 干细胞生物科技公司 制备注射液的方法

Also Published As

Publication number Publication date
US20140030237A1 (en) 2014-01-30
EP2400971A1 (fr) 2012-01-04
JP2012518646A (ja) 2012-08-16
TWI496888B (zh) 2015-08-21
EP2400971A4 (fr) 2013-03-27
CN102325537A (zh) 2012-01-18
CN102325537B (zh) 2014-07-30
WO2010099044A2 (fr) 2010-09-02
US20100215622A1 (en) 2010-08-26
EP2400971B1 (fr) 2016-05-18
US8563307B2 (en) 2013-10-22
JP5809068B2 (ja) 2015-11-10
TW201040278A (en) 2010-11-16
ES2582582T3 (es) 2016-09-13
US9770473B2 (en) 2017-09-26

Similar Documents

Publication Publication Date Title
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
IL217824A0 (en) Treatment of of macrophage-related disorders
EP2435825B8 (fr) Procédés de traitement de maladies
ZA201203289B (en) Use of bethanechol for treatment of zerostomia
WO2011003064A9 (fr) Procédés de traitement d'une douleur neuropathique
WO2010099044A9 (fr) Traitement de troubles liés à l'immunosuppression
GB0915515D0 (en) Treatment of vasculoproliferative conditions
HK1166472A1 (en) Treatment of dyskinesia related disorders
GB0919097D0 (en) Treatment of hard surfaces
WO2011071995A9 (fr) Composés et procédés de traitement de troubles oculaires
IL206491A0 (en) Treatment of produce
ZA201106076B (en) Treatment of insulin-resistant disorders
IL225896A0 (en) Treatment of mecp-2 related disorders
WO2011062906A9 (fr) Traitement de la fibrillation atriale
GB0901456D0 (en) Treatment of psoriasis
WO2011153429A9 (fr) Méthodes de traitement
GB0809476D0 (en) Treatment of neurodegenerative disorders
IL200753A0 (en) Treatment of psoriasis
PL2477656T3 (pl) Leczenie stanów neurologicznych
WO2011047309A9 (fr) Traitement de tissu ischémique
EP2424539A4 (fr) Procédé de traitement d'une dépression
EP2440238A4 (fr) Méthodes de traitement
AU2009904460A0 (en) Methods of treatment
AU2009902633A0 (en) Methods of treatment
AU2009905173A0 (en) Methods of treatment

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080008875.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10746666

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010746666

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011551250

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE